BR112016007646A2 - forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe - Google Patents
forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxeInfo
- Publication number
- BR112016007646A2 BR112016007646A2 BR112016007646A BR112016007646A BR112016007646A2 BR 112016007646 A2 BR112016007646 A2 BR 112016007646A2 BR 112016007646 A BR112016007646 A BR 112016007646A BR 112016007646 A BR112016007646 A BR 112016007646A BR 112016007646 A2 BR112016007646 A2 BR 112016007646A2
- Authority
- BR
- Brazil
- Prior art keywords
- anhydrous
- crystalline form
- cabazitaxel
- cabazitaxe
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção refere-se a uma nova forma cristalina anidra de cabazitaxel de fórmula (i), designada como forma h. um objeto adicional da presente invenção é um processo para o preparo da forma h mencionada acima por recristalização de cabazitaxel a partir de uma mistura de decanoil e octanoil triglicerídeos ou a partir de trioctanoato de glicerol. a forma h de cabazitaxel é útil para preparar cabazitaxel, sais de cabazitaxel e formas polimórficas deste. é também particularmente útil como medicamento, especialmente para o tratamento de cânceres.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13189949.4 | 2013-10-23 | ||
EP20130189949 EP2865675A1 (en) | 2013-10-23 | 2013-10-23 | A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
PCT/EP2014/071601 WO2015058961A1 (en) | 2013-10-23 | 2014-10-09 | A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016007646A2 true BR112016007646A2 (pt) | 2017-08-01 |
BR112016007646B1 BR112016007646B1 (pt) | 2022-12-27 |
Family
ID=49447494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016007646-0A BR112016007646B1 (pt) | 2013-10-23 | 2014-10-09 | Forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe |
Country Status (20)
Country | Link |
---|---|
US (1) | US9586919B2 (pt) |
EP (2) | EP2865675A1 (pt) |
JP (2) | JP2016534065A (pt) |
KR (2) | KR20160063356A (pt) |
CN (1) | CN105849093A (pt) |
AU (1) | AU2014339222B2 (pt) |
BR (1) | BR112016007646B1 (pt) |
CA (1) | CA2928305C (pt) |
CL (1) | CL2016000951A1 (pt) |
DK (1) | DK3060556T3 (pt) |
ES (1) | ES2645478T3 (pt) |
HU (1) | HUE035010T2 (pt) |
IL (1) | IL245260B (pt) |
MX (1) | MX363334B (pt) |
PL (1) | PL3060556T3 (pt) |
PT (1) | PT3060556T (pt) |
RU (1) | RU2672110C2 (pt) |
SG (1) | SG11201603168WA (pt) |
SI (1) | SI3060556T1 (pt) |
WO (1) | WO2015058961A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3010514A1 (en) | 2016-01-15 | 2017-07-20 | Zhuhai Beihai Biotech Co., Ltd. | Compositions and formulations including cabazitaxel and human serum albumin |
US11413265B2 (en) | 2018-04-20 | 2022-08-16 | Zhuhai Beihai Biotech Co., Ltd. | Formulations and compositions of Cabazitaxel |
WO2020249507A1 (en) * | 2019-06-11 | 2020-12-17 | Indena S.P.A. | Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA23823A1 (fr) | 1995-03-27 | 1996-10-01 | Aventis Pharma Sa | Nouveaux taxoides, leur preparation et les compositions qui les contiennent |
FR2771092B1 (fr) | 1997-11-18 | 1999-12-17 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la classe des taxoides |
FR2859996B1 (fr) * | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
KR101266549B1 (ko) * | 2006-10-20 | 2013-05-24 | 시노팜 싱가포르 피티이 리미티드 | 결정형 무수 도세탁셀을 제조하는 방법 |
FR2926551A1 (fr) * | 2008-01-17 | 2009-07-24 | Aventis Pharma Sa | Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation |
EP2688877B1 (en) | 2011-04-12 | 2017-03-08 | Teva Pharmaceuticals International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
EP2548905A1 (de) | 2011-07-18 | 2013-01-23 | Bayer MaterialScience AG | Verfahren zur Aktivierung von Doppelmetallcyanidkatalysatoren zur Herstellung von Polyetherpolyolen |
TWI526437B (zh) | 2011-09-09 | 2016-03-21 | 台灣神隆股份有限公司 | 卡巴他賽之結晶型 |
JP6025861B2 (ja) | 2011-12-13 | 2016-11-16 | アベンティス・ファーマ・ソシエテ・アノニム | カバジタキセルの結晶形およびこれを調製するための方法 |
EP2822932A2 (en) | 2012-03-08 | 2015-01-14 | IVAX International GmbH | Solid state forms of cabazitaxel and processes for preparation thereof |
CN102675257B (zh) | 2012-05-10 | 2014-07-02 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
CN102898406B (zh) * | 2012-11-02 | 2014-12-03 | 上海金和生物技术有限公司 | 一种卡巴他赛晶体及其制备方法 |
-
2013
- 2013-10-23 EP EP20130189949 patent/EP2865675A1/en not_active Withdrawn
-
2014
- 2014-10-09 HU HUE14789196A patent/HUE035010T2/en unknown
- 2014-10-09 KR KR1020167010513A patent/KR20160063356A/ko not_active Application Discontinuation
- 2014-10-09 JP JP2016525551A patent/JP2016534065A/ja active Pending
- 2014-10-09 US US15/030,620 patent/US9586919B2/en active Active
- 2014-10-09 RU RU2016115538A patent/RU2672110C2/ru active
- 2014-10-09 BR BR112016007646-0A patent/BR112016007646B1/pt active IP Right Grant
- 2014-10-09 WO PCT/EP2014/071601 patent/WO2015058961A1/en active Application Filing
- 2014-10-09 SI SI201430358T patent/SI3060556T1/sl unknown
- 2014-10-09 PL PL14789196T patent/PL3060556T3/pl unknown
- 2014-10-09 AU AU2014339222A patent/AU2014339222B2/en active Active
- 2014-10-09 SG SG11201603168WA patent/SG11201603168WA/en unknown
- 2014-10-09 DK DK14789196.4T patent/DK3060556T3/en active
- 2014-10-09 CA CA2928305A patent/CA2928305C/en active Active
- 2014-10-09 PT PT147891964T patent/PT3060556T/pt unknown
- 2014-10-09 MX MX2016005231A patent/MX363334B/es unknown
- 2014-10-09 ES ES14789196.4T patent/ES2645478T3/es active Active
- 2014-10-09 EP EP14789196.4A patent/EP3060556B1/en active Active
- 2014-10-09 KR KR1020217041873A patent/KR20210158417A/ko not_active Application Discontinuation
- 2014-10-09 CN CN201480057873.4A patent/CN105849093A/zh active Pending
-
2016
- 2016-04-21 CL CL2016000951A patent/CL2016000951A1/es unknown
- 2016-04-21 IL IL245260A patent/IL245260B/en active IP Right Grant
-
2018
- 2018-12-07 JP JP2018229594A patent/JP6698803B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2015058961A1 (en) | 2015-04-30 |
SI3060556T1 (sl) | 2017-10-30 |
IL245260B (en) | 2018-11-29 |
JP2016534065A (ja) | 2016-11-04 |
JP6698803B2 (ja) | 2020-05-27 |
EP3060556B1 (en) | 2017-08-02 |
SG11201603168WA (en) | 2016-05-30 |
CL2016000951A1 (es) | 2016-11-25 |
IL245260A0 (en) | 2016-06-30 |
PT3060556T (pt) | 2017-11-10 |
AU2014339222A1 (en) | 2016-05-12 |
US9586919B2 (en) | 2017-03-07 |
EP2865675A1 (en) | 2015-04-29 |
RU2672110C2 (ru) | 2018-11-12 |
ES2645478T3 (es) | 2017-12-05 |
US20160244420A1 (en) | 2016-08-25 |
AU2014339222B2 (en) | 2017-12-14 |
CA2928305C (en) | 2021-06-15 |
HUE035010T2 (en) | 2018-03-28 |
BR112016007646B1 (pt) | 2022-12-27 |
EP3060556A1 (en) | 2016-08-31 |
CN105849093A (zh) | 2016-08-10 |
MX363334B (es) | 2019-03-19 |
MX2016005231A (es) | 2016-08-11 |
RU2016115538A3 (pt) | 2018-06-14 |
KR20210158417A (ko) | 2021-12-30 |
KR20160063356A (ko) | 2016-06-03 |
PL3060556T3 (pl) | 2018-01-31 |
JP2019055989A (ja) | 2019-04-11 |
DK3060556T3 (en) | 2017-09-04 |
CA2928305A1 (en) | 2015-04-30 |
RU2016115538A (ru) | 2017-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
BR112017017396A2 (pt) | derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos | |
CR20130534A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
BR112017010354A2 (pt) | compostos de triazolopirimidina e usos dos mesmos | |
CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
EA201590453A1 (ru) | Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b | |
EA201690094A1 (ru) | Ингибиторы syk | |
EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
BR112012023950A2 (pt) | formas cristalinas de um macrolídeo, e usos dos mesmos | |
DOP2014000012A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
CY1116439T1 (el) | Τριαζολοπυριδινες | |
CU20130036A7 (es) | Triazina-oxidazoles | |
BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
EA201492023A1 (ru) | Регуляторы пути комплемента и их применение | |
BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
BR112013011593A2 (pt) | cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo | |
DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
EA201391371A1 (ru) | Фармацевтическая композиция ситаглиптина | |
EA201600394A1 (ru) | Трициклические соединения пиперидина | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2014, OBSERVADAS AS CONDICOES LEGAIS |